Terminated PHASE1 INTERVENTIONAL 2-arm NCT04570631

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor: AbbVie

Conditions Multiple Myeloma

Interventions Bortezomib Dexamethasone Eftozanermin alfa

Updated 19 times since 2020 Last updated: May 14, 2025 Started: Nov 5, 2020 Primary completion: May 5, 2025 Completion: May 5, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic considerations

Other terminated trials from AbbVie

See all terminations from AbbVie

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

Listed as NCT04570631, this PHASE1 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by AbbVie, it has been updated 19 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

19 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Jun 2025 — Sep 2025 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Apr 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Apr 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1

▶ Show 14 earlier versions

Aug 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1
May 2023 — Aug 2023 [monthly]

Active Not Recruiting PHASE1
Nov 2022 — May 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE1
May 2022 — Jun 2022 [monthly]

Recruiting PHASE1
Apr 2022 — May 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Apr 2022 [monthly]

Recruiting PHASE1
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Feb 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Berlin, Germany , Boston, United States , Dallas, United States , Durham, United States , Hamburg, Germany , Kashiwa-shi, Japan , L'Hospitalet de Llobregat, Spain , Lille, France , Louisville, United States and 9 more locations